Keywords: Amylin Pharma, Fourth-quarter and full year 2011 financial results, Byetta, Bydureon

Amylin 4th-qtr loss widens on charges

Article | 07 February 2012

Print This

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) reported that in loss for the fourth quarter of 2011 leapt to $461.5 million, or $3.15 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in